Brooklyn Investment Group Purchases 71 Shares of Zoetis Inc. (NYSE:ZTS)

Brooklyn Investment Group lifted its position in Zoetis Inc. (NYSE:ZTS) by 2.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,655 shares of the company’s stock after acquiring an additional 71 shares during the period. Brooklyn Investment Group’s holdings in Zoetis were worth $596,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Darwin Wealth Management LLC purchased a new position in Zoetis in the 3rd quarter worth about $31,000. First Personal Financial Services purchased a new position in shares of Zoetis during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis during the third quarter valued at approximately $33,000. Dunhill Financial LLC boosted its holdings in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Quarry LP grew its position in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 2.0 %

Shares of ZTS stock opened at $166.01 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The company’s fifty day moving average price is $171.15 and its 200-day moving average price is $179.99. The company has a market capitalization of $74.90 billion, a price-to-earnings ratio of 31.20, a PEG ratio of 2.51 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period last year, the firm earned $1.36 earnings per share. Sell-side analysts expect that Zoetis Inc. will post 5.91 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.